case_images: PMC10891373_01
case_images: erythematous patches on the lower occipital region and the posterior neck at the first visit
case_images: PAMJ-46-95-g001.jpg
case_images: PMC10891373_01_PAMJ-46-95-g001.jpg
case_images: F1
case_images: Examination showed erythematous patches of 1 to 5 cm in diameter on these areas (Figure 1).
case_images: after the temporary cessation of bosutinib due to myalgia, the cutaneous lesions largely resolved
case_images: PAMJ-46-95-g002.jpg
case_images: PMC10891373_01_PAMJ-46-95-g002.jpg
case_images: F2
case_images: The lesions significantly subsided following a temporary discontinuation of bosutinib due to myalgia (Figure 2).
case_images: six weeks after the re-administration of bosutinib, cutaneous lesions reappeared and aggravated at the same site
case_images: PAMJ-46-95-g003.jpg
case_images: PMC10891373_01_PAMJ-46-95-g003.jpg
case_images: F3
case_images: Subsequently, six weeks later, the lesions reemerged and exacerbated at the same site (Figure 3).
case_images: the histopathologic findings: lymphocytes have infiltrated from the dermo-epidermal junction to the superficial dermis; sparse dyskeratotic cells are seen (hematoxylin-eosin stain, x100)
case_images: PAMJ-46-95-g004.jpg
case_images: PMC10891373_01_PAMJ-46-95-g004.jpg
case_images: F4
case_images: Notably, there were no signs of pigmentary incontinence or dermal melanophages (Figure 4).